. . . . . . . "9066"^^ . . . . . "Na z\u00E1klad\u011B zku\u0161enost\u00ED s glimepiridem a s jin\u00FDmi sulfonylmo\u010Dovinami je t\u0159eba zm\u00EDnit n\u00E1sleduj\u00EDc\u00ED interakce:\nPotenciace hypoglykemizuj\u00EDc\u00EDho \u00FA\u010Dinku\nV n\u011Bkter\u00FDch p\u0159\u00EDpadech se m\u016F\u017Ee objevit hypoglyk\u00E9mie, jestli\u017Ee se sou\u010Dasn\u011B s glimepiridem u\u017E\u00EDv\u00E1 n\u011Bkter\u00E9 z t\u011Bchto l\u00E9\u010Div, nap\u0159\u00EDklad: fenylbutazon, azapropanon a oxyfenbutazon, sulfinpyrazon, inzulin a peror\u00E1ln\u00ED antidiabetika jako metformin, ur\u010Dit\u00E9 sulfonamidy s dlouhodob\u00FDm \u00FA\u010Dinkem, tetracykliny, salicyl\u00E1ty a paraaminosalicylov\u00E1 kyselina, inhibitory MAO, anabolick\u00E9 steroidy a mu\u017Esk\u00E9 pohlavn\u00ED hormony, chinolinov\u00E1 antibiotika, chloramfenikol, probenecid, kumarinov\u00E1 antikoagulancia, mikonazol, fenfluramin, pentoxifylin (vysok\u00E9 d\u00E1vky parenter\u00E1ln\u011B), fibr\u00E1ty, tritochalin, ACE inhibitory, flukonazol, fluoxetin, alopurinol, sympatolytika, cyklofosfamid, trofosfamid a ifosfamid, klarithromycin."@cs . . "1"^^ . . . . . . "9899"^^ . . . . . . . . . . . . . .